France has confirmed its first Ebola case linked to the ongoing outbreak in the Democratic Republic of Congo (DRC), marking the first known infection detected outside Africa since the emergence of the current epidemic involving the rare Bundibugyo strain of the virus.
French health authorities said the patient, a humanitarian doctor who recently returned from the DRC, has been isolated and is in stable condition. The case represents a significant development in the outbreak, which has spread across parts of the DRC and Uganda and has raised international concerns due to the absence of an approved vaccine or specific treatment for the Bundibugyo strain.
In a statement, the French Ministry of Health sought to reassure the public, saying, “All precautionary measures, including the patient’s isolation, were taken upon his arrival in France, with transfer to the hospital under secure conditions to avoid any risk of contamination.”
The ministry later confirmed that the infection was identified in mainland France and disclosed that a dedicated monitoring system had been established to track French humanitarian workers returning from affected regions.
Health authorities have launched contact-tracing efforts and are working to identify anyone who may have been exposed to the patient. Those considered at risk will be required to self-isolate for 21 days, the standard incubation monitoring period for Ebola.
French officials said the situation is being monitored “very closely” by Prime Minister Sébastien Lecornu and senior government officials as efforts continue to prevent any local transmission.
The latest case comes as the DRC battles its 17th Ebola outbreak, which was officially declared on May 15 following a series of unexplained deaths in the conflict-ridden eastern province of Ituri. According to the latest official figures, the outbreak has infected 1,048 people and claimed 267 lives.
The World Health Organization (WHO) warned in mid-June that transmission of the disease is accelerating despite intensified response measures by health authorities. Public health experts have attributed part of the challenge to widespread mistrust of medical institutions in affected communities, where many residents continue to seek treatment from traditional healers instead of healthcare facilities.
The situation has been further complicated by years of insecurity in eastern Congo, where armed groups operate and frequent attacks have disrupted public services and humanitarian interventions.
Ebola is a severe viral hemorrhagic fever with a high fatality rate. Symptoms can include fever, weakness, muscle pain, vomiting, diarrhea and, in severe cases, internal and external bleeding.
The European Centre for Disease Prevention and Control (ECDC) has assessed the risk of infection as low for European residents and travelers visiting affected areas, and very low for the general European population.
Scientists are meanwhile racing to develop a vaccine against the Bundibugyo strain. The WHO has identified a new vaccine candidate based on the rVSV platform used to create the only currently licensed Ebola vaccine. Unlike existing vaccines designed to target the more common Zaire strain, the experimental candidate has been modified specifically for Bundibugyo.
However, the global health agency estimates it could take between seven and nine months before the vaccine is ready for human trials, leaving health authorities reliant on surveillance, isolation and contact tracing to contain the outbreak.
France’s confirmation of the first international case linked to the epidemic underscores growing concerns among health officials as the outbreak continues to expand in Central Africa, despite intensified containment efforts.
